News articles about Medivation (NASDAQ:MDVN) have been trending negative this week, according to Alpha One Sentiment. Alpha One, a division of Accern, identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medivation earned a daily sentiment score of -0.31 on Alpha One’s scale. Alpha One also assigned news articles about the biopharmaceutical company an impact score of 41 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/05/04/critical-media-coverage-somewhat-unlikely-to-affect-medivation-mdvn-stock-price.html.

Medivation Company Profile

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

5 Day Chart for NASDAQ:MDVN

Receive News & Ratings for Medivation Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivation Inc and related companies with MarketBeat.com's FREE daily email newsletter.